Time filter

Source Type

Tachikawa, Japan

Matsuoka H.,Utsunomiya Chuoh Hospital | Kuwajima I.,Tokyo Metropolitan Geriatric Hospital | Shimada K.,Shin oyama City Hospital | Mitamura H.,Tachikawa Hospital | Saruta T.,Keio University
Journal of Clinical Hypertension

TY-0201 (TY) is a new drug absorbed by the transdermal delivery system developed for the treatment of hypertension, which contains the free base of bisoprolol fumarate that is widely used. An 8-week randomized, double-blind, placebo-controlled study was conducted in hypertensive patients to evaluate the superiority of TY 8 mg to placebo and the noninferiority of TY 8 mg to bisoprolol fumarate oral formulation (BO) 5 mg. Changes in diastolic blood pressure (BP) (primary endpoint) from baseline in the TY 8 mg group, the BO 5 mg group, and the placebo group were -12.2 mm Hg, -11.8 mm Hg, and -3.7 mm Hg, respectively, with TY 8 mg demonstrating superiority to placebo and noninferiority to BO 5 mg. Changes from baseline for systolic BP and pulse rate produced significant reductions compared with placebo. TY is expected to serve as a new treatment approach for hypertensive patients. © 2013 Wiley Periodicals, Inc. Source

Noda T.,National Cerebral and Cardiovascular Center | Kurita T.,Kinki University | Nitta T.,Nippon Medical School | Abe H.,University of Occupational and Environmental Health Japan | And 8 more authors.
Circulation Journal

Background: Little is known regarding the appropriate duration for driving restrictions after inappropriate implantable cardiac shock device (ICSD) therapy. Methods and Results: We evaluated the Nippon Storm Study data, and found that inappropriate ICSD therapy occurred in 114 (7.6%) patients during a median follow-up of 464 days. Among those patients, 25 experienced further inappropriate ICSD therapy during a subsequent median follow-up of 380 days. Time-dependent recurrence of inappropriate ICSD therapy occurred in 19 (76%) patients within 180 days. Conclusions: The interval for driving restrictions after inappropriate ICSD therapy can be reduced. Source

Lancaster E.,University of Pennsylvania | Lai M.,University of Pennsylvania | Peng X.,University of Pennsylvania | Hughes E.,University of Pennsylvania | And 13 more authors.
The Lancet Neurology

Background: Some encephalitides or seizure disorders once thought idiopathic now seem to be immune mediated. We aimed to describe the clinical features of one such disorder and to identify the autoantigen involved. Methods: 15 patients who were suspected to have paraneoplastic or immune-mediated limbic encephalitis were clinically assessed. Confocal microscopy, immunoprecipitation, and mass spectrometry were used to characterise the autoantigen. An assay of HEK293 cells transfected with rodent GABAB1 or GABAB2 receptor subunits was used as a serological test. 91 patients with encephalitis suspected to be paraneoplastic or immune mediated and 13 individuals with syndromes associated with antibodies to glutamic acid decarboxylase 65 were used as controls. Findings: All patients presented with early or prominent seizures; other symptoms, MRI, and electroencephalography findings were consistent with predominant limbic dysfunction. All patients had antibodies (mainly IgG1) against a neuronal cell-surface antigen; in three patients antibodies were detected only in CSF. Immunoprecipitation and mass spectrometry showed that the antibodies recognise the B1 subunit of the GABAB receptor, an inhibitory receptor that has been associated with seizures and memory dysfunction when disrupted. Confocal microscopy showed colocalisation of the antibody with GABAB receptors. Seven of 15 patients had tumours, five of which were small-cell lung cancer, and seven patients had non-neuronal autoantibodies. Although nine of ten patients who received immunotherapy and cancer treatment (when a tumour was found) showed neurological improvement, none of the four patients who were not similarly treated improved (p=0·005). Low levels of GABAB1 receptor antibodies were identified in two of 104 controls (p<0·0001). Interpretation: GABAB receptor autoimmune encephalitis is a potentially treatable disorder characterised by seizures and, in some patients, associated with small-cell lung cancer and with other autoantibodies. Funding: National Institutes of Health. © 2010 Elsevier Ltd. All rights reserved. Source

Hirota S.,Ueki Hospital | Sadanaga T.,Ueki Hospital | Sadanaga T.,Keio University | Mitamura H.,Tachikawa Hospital | Fukuda K.,Keio University
Hypertension Research

The purpose of this study was to evaluate long-term compliance with salt restriction in Japanese cardiology outpatients assessed by spot urine measurements. A total of 466 patients (72±10 years old, 216 females) who visited a cardiology outpatient clinic and were followed for at least 1 year were included in this study. Daily dietary salt intake was estimated based on the sodium and creatinine concentrations determined by spot urine at the time of enrollment, during an 8-26 week follow-up and at a long-term follow-up (>1 year). The average follow-up duration was 2.2±0.6 (1.0-3.4) years after enrollment, and spot urines were collected 5.2±2.8 times after 1 year. The baseline estimated salt excretion was 9.6±2.7 g per day, which was reduced to 8.7±2.3 g per day (P<0.01) at 8-26 weeks and remained unchanged at the long-term follow-up (8.9±2.0 g per day, P=0.36 vs. 8-26 weeks, P<0.01 vs. baseline). The percent of patients who achieved an average salt excretion<6.0 g per day was unchanged from baseline (6.9% vs. 7.7%, P=0.61). Among several variables (gender, age, body weight, salt excretion at enrollment) that might affect the incidence of salt excretion <6.0 g per day, salt excretion at baseline was the only determinant of successful salt restriction (P<0.01). In conclusion, compliance with salt restriction, assessed using a spot urine method, was maintained over the long term; however, achieving salt reduction to the level recommended by the guidelines remains a challenge. © 2013 The Japanese Society of Hypertension All rights reserved. Source

Oguro S.,Keio University | Nakatsuka S.,Keio University | Yashiro H.,Keio University | Hashimoto S.,Tachikawa Hospital | And 4 more authors.
Journal of Vascular and Interventional Radiology

The present report describes 6 cases of adrenal venous sampling (AVS) in patients who underwent computed tomography (CT) during arteriography because cannulation of right adrenal veins was otherwise difficult. CT was performed during arteriography to obtain information on the location and direction of the right adrenal vein. Two right adrenal veins were visualized in 1 case. The right central adrenal vein was not visualized in 1 case owing to an injury from a previous unsuccessful AVS procedure, but the right renal capsular vein was well visualized. CT during arteriography could contribute to a high AVS success rate. © 2015 SIR. Source

Discover hidden collaborations